eloralintide vs tirzepatide 2025 ADA Highlights: A New Era for GLP-1 Therapies in Obesity and Diabetes GLP-1-based therapies for diabetes, obesity
Description
Mounjaro and Zepbound are registered trademarks of Eli Lilly
Clinical trials back both semaglutide and tirzepatide for weight loss
Common concentrations include 5 mg/ml, 10 mg/ml, and 20 mg/ml
Other GLP-1 medications , including Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro, Victoza, Byetta, or Bydureon
These are resolution rates that no other medication has achieved
